False Claims Act Can Hamper Science With 'Bounty Hunter' Lawsuits

Fraud and misconduct in scientific research have become a problem attracting national and international attention. Although concern over research misconduct was once confined to the scientific community, it has since become the focus of media scrutiny and the obsession of congressional committees. With this growing interest has come increased governmental intervention, particularly where public research funds are involved. Whereas deceitful scientists were once subjected only to the disapprov

Written byDan Burk
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Whereas deceitful scientists were once subjected only to the disapproval of their peers, their activities may now invoke serious criminal and civil sanctions. Among these are civil "bounty hunter" provisions of the Federal False Claims Act, which permit private individuals to sue for a share of squandered federal funds. By substituting a financial incentive for the self-policing norms of the scientific community, this statute promises to have a negative impact on the way scientific research is conducted.

Research misconduct takes a variety of forms, any of which could potentially trigger legal liability. It is generally considered to be most serious when the actions constitute true scientific fraud--that is, a report of experiments never conducted, observations never performed, calculations never made. Such a fabricated report is rarely limited to imaginary numbers, charts, or graphs. The study usually will not be believed without physical evidence of the experiment. For the fraud to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies